Thanks for emailing that article!
ACADIA Pharmaceuticals, a biopharmaceutical company based in San Diego, California focused on treatments for neurological and central nervous system disorders, today announced that Allergan, Inc. has advanced an additional product candidate as a potential new treatment for glaucoma.
The novel small molecule resulted from joint research conducted by the companies under their recently concluded research collaboration focused on new therapies for glaucoma and related ophthalmic conditions.
“We are delighted that Allergan has advanced another new chemical entity emerging from our collaborative research into preclinical development,” said Uli Hacksell, PhD, Chief Executive Officer of ACADIA. “This molecule has demonstrated an attractive profile and has distinctly different properties from other glaucoma compounds advanced under the collaboration.”
Allergan is responsible for development and has worldwide rights to commercialize products advanced under the companies' glaucoma collaboration.
Source: ACADIA Pharmaceuticals
Last reviewed on June 03, 2013